Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Quesitons

Domperidone:
1. Available in the United States only via investigational drug programs with the FDA; the agent is available in many other countries.
2. Domperidone''s effect on prokinetic activity has been described as "modest."
3. Both
4. Neither
Domperidone:
1. Domperidone administration does not result in the class of extrapyramidal side effects, says this drug is not cross the blood-brain barrier.
2. Domperidone influences prolactin release and effects temperature and regulation of emesis.
3. Both
4. Neither
Domperidone pharmacology:
1. No appreciable effects on lower G.I. motility.
2. Especially active in children
3. Both
4. Either
Side effect(s) of domperidone
1. Elevated Risk of serious ventricular tachyarrhythmias which may progressed to sudden cardiac death. This effect is more likely observed in older individuals (defined as >60 years of age).
2. Domperidone administration can cause gynecomastia, amenorrhea, impotence and galactorrhea, secondary to increase prolactin. This effect is comparable to those observed with metoclopramide.
3. Both
4. Neither
Erythromycin, classified as a macrolide antibiotic, directly stimulates motilin receptors on G.I. smooth muscle. Consequence(s):
1. Beneficial following IV administration in a subset of patients with gastroparesis.
2. Erythromycin administration in this setting is associated with rapid tolerance development
3. Both
4. Neither
Pharmacological alteration in serotonin affects in the gut represents a potentially important drug development approach.
1. True
2. False
Concerning serotonin-related pharmacological agents that may address G.I. motility issues:
1. Tegaserod (Zelnorm; Zelmac) is classified as an "emergency investigational new drug."
2. Cisapride (Propulsid) may be available in "llimit-access protocol."
3. Both
4. Neither
Limitations concerning availability of serotonergic prokinetic agents reflect concerns to serious, adverse cardiac effects.
1. True
2. False
Prucalopride (Resolor; Resotran):
1. At present approved in Europe and Canada (symptomatic treatment of chronic constipation in women when laxatives are inadequate)
2. Prucalopride is classified as a 5-HT₄ agonist.
3. Both
4. Neither
Example(s) of 5-HT₄ serotonin subtype agonist:
1. Prucalopride
2. Cisapride
3. Both
4. Neither

Medical Pharmacology: Gastrointestinal Pharmacology Practice Questions